FGFR Gatekeeper Mutant Inhibitors Overcoming AZD4547 Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells develop resistance to FGFR inhibitors due to gatekeeper mutations, limiting the effectiveness of existing anticancer agents targeting FGFR tyrosine kinase.
Innovation Solution
Identification of novel gatekeeper mutations in FGFR genes and development of a pharmaceutical composition, represented by Formula (I) or its pharmaceutically acceptable salts, which targets FGFR mutant polypeptides with specific amino acid substitutions, such as V564F and V562L, to overcome resistance and inhibit cancer cell growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing FGFR inhibitors are used to treat cancer, then cancer cell growth is inhibited in wild-type FGFR, but resistance develops due to gatekeeper mutations
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of FGFR inhibitors to create new compounds with altered binding characteristics. The inventors developed compounds with modified pharmacophoric groups and side chains that can accommodate gatekeeper mutations while maintaining inhibitory activity, thereby changing the interaction parameters between the drug and target protein to overcome resistance
Solution Approach 2:
The patent applies local quality by designing inhibitors with specific structural features tailored to bind mutated FGFR variants. The compounds contain modified interaction regions that specifically recognize and bind to gatekeeper mutation sites (such as V564F, V562L), allowing selective inhibition of mutant forms while maintaining efficacy against wild-type FGFR
2Reliability
If novel inhibitors are developed to target mutant FGFR, then resistance to other inhibitors is overcome, but drug specificity must be maintained
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a core pharmacophore for FGFR binding, side chains for accommodating mutations, and pharmacophoric groups for maintaining specificity. This modular approach allows systematic optimization of each region to achieve both mutant targeting and selectivity
Solution Approach 2:
The patent applies universality by designing a series of compounds with a common core structure that can target multiple FGFR isoforms and mutation types. The inhibitors are designed to maintain a universal binding mode across different FGFR variants while allowing flexibility in side chain configurations to adapt to specific mutations
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.